170 related articles for article (PubMed ID: 38135627)
21. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma.
Eisenberg MS; Meng MV; Master VA; Stoller ML; Rini BI; Carroll PR; Kane CJ
J Endourol; 2006 Jul; 20(7):504-8. PubMed ID: 16859465
[TBL] [Abstract][Full Text] [Related]
22. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
24. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
25. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
[TBL] [Abstract][Full Text] [Related]
26. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
27. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
[TBL] [Abstract][Full Text] [Related]
28. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
[TBL] [Abstract][Full Text] [Related]
29. The role of cytoreductive nephrectomy in the immuno-oncological therapy era.
Magee DE; Helstrom E; Kutikov A
Curr Opin Urol; 2023 Mar; 33(2):136-141. PubMed ID: 36710594
[TBL] [Abstract][Full Text] [Related]
30. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
31. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
32. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
34. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Liu J; Moon D; Lawrentschuk N
Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
[No Abstract] [Full Text] [Related]
35. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
36. Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis.
Li KP; He M; Wan S; Chen SY; Wang CY; Li XR; Yang L
Int J Surg; 2023 Oct; 109(10):3178-3188. PubMed ID: 37462997
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
Powles T; Sarwar N; Stockdale A; Sarker SJ; Boleti E; Protheroe A; Jones R; Chowdhury S; Peters J; Oades G; O'Brien T; Sullivan M; Aitchison M; Beltran L; Worth D; Smith K; Michel C; Trevisan G; Harvey-Jones E; Wimalasingham A; Sahdev A; Ackerman C; Crabb S
JAMA Oncol; 2016 Oct; 2(10):1303-1309. PubMed ID: 27254750
[TBL] [Abstract][Full Text] [Related]
38. Cytoreductive nephrectomy in the era of targeted therapies: a review.
Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
[TBL] [Abstract][Full Text] [Related]
40. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Gore LR; Reich RR; Dunn RL; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain RK; Chahoud J; Spiess PE; Manley BJ; Sexton WJ; Hollenbeck BK; Gilbert SM
JAMA Netw Open; 2022 May; 5(5):e2212347. PubMed ID: 35576003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]